Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Lloyd's of London estimates $2.3bn market loss from Californian wildfires

(Sharecast News) - Lloyd's of London has pencilled in a $2.3bn (£1.8bn) net loss to the insurance market from the Californian wildfires but says it is still too early to give an accurate prediction. "Although we are still assessing the full impact, we do not expect this to be a capital event," said Burkhard Keese, Lloyd's chief financial officer.

The prediction came as the insurance and reinsurance marketplace published its preliminary results for 2024, in which it reported a 6.5% increase in gross written premiums to £55.5bn.

That reflected 8.5% operational growth, primarily in the property and reinsurance segments which had a strong underwriting performance in the year, and a 0.3% positive impact from pricing, slightly offset by a 2.3% hit from FX movements.

The average combined ratio of the market - a key insurance indicator where a number below 100% reflects underwriting profitability - was 86.9%, up from 84.0% in 2023, which was driven by a number of major claims in the second half. However, excluding large losses, the underlying combined ratio fell to 79.1% from 80.5%.

Lloyd's reported a pre-tax profit for the year of £9.6bn, down from £10.7bn previously.

"2024 saw us maintain our focus on strong profitability and disciplined growth. Our market has delivered another excellent underwriting year for our investors, while providing best in class solutions for our customers to protect their business flows and balance sheets," Keese said.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.